RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
November 09, 2023 12:58 ET | RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration and Alzheimer’s Syndrome.
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
November 08, 2023 05:45 ET | RetinalGeniX Technologies, Inc.
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 03, 2023 12:00 ET | Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023 14:51 ET | RetinalGeniX Technologies, Inc.
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
Global Retinal Implants Market
Global Retinal Implant Market Anticipates Rapid Growth, Expected to Reach $112.2 Million by 2030
October 30, 2023 11:18 ET | Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Retinal Implants Market Size, Share & Trends Analysis Report By Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, Argus II),...
Global Pupillometer Market
Global Pupillometer (Table-top, Hand-held) Market Size, Share & Trends Analysis Report 2023-2030
October 11, 2023 06:58 ET | Research and Markets
Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The "Pupillometer Market Size, Share & Trends Analysis Report By Mobility (Table-top, Hand-held), By Type (Video, Digital), By End Use (Hospitals, Eye...
logo color s and clearside.jpg
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
October 04, 2023 09:00 ET | Clearside Biomedical, Inc.
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
logo color s and clearside.jpg
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
October 03, 2023 16:35 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023 05:59 ET | RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding...
ONL logo.jpg
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
August 28, 2023 07:00 ET | ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...